Full Year 2017 Trading Update
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
(“Mediclinic”, the “Company” or the “Group”)
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
13 April 2017
Full Year 2017 Trading Update
Mediclinic International plc, the international private healthcare group, provides the following
trading update ahead of the publication of its results for the year ended 31 March 2017
(“FY17”) on 24 May 2017. The information on which this trading update is based represents
the Group’s latest financial estimates and has not been reviewed and reported on by
Mediclinic’s external auditors. All financial figures, unless explicitly stated, are underlying*.
Commenting today, Danie Meintjes, CEO, said:
“Mediclinic’s largest two platforms, Switzerland and Southern Africa, in addition to our Dubai
business, all performed in line with expectations during the 2017 financial year. However, as
previously announced, the Abu Dhabi business underperformed having been impacted by a
major regulatory change in addition to certain business and operational challenges. We have
been focused on resolving these issues and stabilising performance in the Middle East. Our
confidence in the long-term growth opportunities of the region remains strong and we
currently expect performance in the Middle East to improve as we progress through the 2018
Hirslanden - Switzerland
FY17 revenue was up 3.5% to some CHF1.7 billion (FY16: CHF1.6 billion) with patient bed days
marginally lower (-0.7%) and revenue per bed day increasing by 3.0%. In addition, Hirslanden’s
outpatient revenues, which represent less than 20% of the overall platform revenues,
continued to grow during the year.
The underlying EBITDA margin for FY17 is expected to be around 20%, marginally higher than
the prior year (FY16: 19.7%). This is due to improved operating leverage and the benefit of a
CHF8m Swiss tariff provision release (FY16: CHF3m), offset by increased costs and the
continued change in mix towards treating basic insured patients.
Hirslanden expects FY17 depreciation and amortisation of around CHF100m, net finance costs
of around CHF55m (of which around CHF20m is intercompany interest which will be
eliminated on consolidation) and income tax expense of around CHF40m.
Mediclinic Southern Africa
FY17 revenue was up 6.8% to some ZAR14.4 billion (FY16: ZAR13.5 billion) with inpatient bed
days and revenue per bed day increasing by around 0.9% and 5.8%, respectively. These results
were delivered against a continued weak macro-economic environment, stagnant medical
scheme membership and increased competition in the private healthcare sector.
The underlying EBITDA margin for FY17 is expected to be around 21%, marginally lower than
the prior year (FY16: 21.4%), impacted by the medical versus surgical mix, higher price
increases on pharmaceuticals (sold at zero margin) and investment in additional clinical
Mediclinic Southern Africa expects FY17 depreciation and amortisation of around ZAR460m,
net finance costs of around ZAR495m and income tax expense of around ZAR625m. Net
finance costs increased compared to the prior year because of refinancing the corporate
bridge loan in June 2016.
Mediclinic Middle East
In line with guidance, FY17 revenue was down 8% compared to pro forma FY16 revenue to
some AED3.1 billion (FY16 pro forma: AED3.4 billion). As previously announced, whilst the
Dubai business performed well in FY17, the Abu Dhabi business experienced challenging
trading conditions impacting revenues. The underlying EBITDA margin for FY17 is expected to
be slightly ahead of previous guidance at 10.5% to 11.5%.
Mediclinic Middle East expects FY17 depreciation and amortisation of around AED175m and
net finance costs of around AED30m, similarly impacted by the refinancing of the corporate
Spire Healthcare Group
Mediclinic has a 29.9% investment in Spire Healthcare Group plc (“Spire”). The investment in
Spire is accounted for on an equity basis recognising the reported profit of £53.6m for Spire’s
financial year ended 31 December 2016. Mediclinic expects the FY17 equity accounted share
of profit from Spire to be £12m (FY16: £6m) after adjusting for the amortisation of intangible
assets recognised in the notional purchase price allocation of the equity investment.
* The Group uses underlying income statement reporting as non-IFRS measures in evaluating
performance and as a method to provide shareholders with clear and consistent reporting. The
Group's non-IFRS measures are intended to remove from reported earnings volatility
associated with defined one-off incomes and charges.
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern
Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose
is to enhance the quality of life of patients by providing acute care, specialist-orientated,
multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire
Healthcare Group plc, a LSE listed and UK-based private healthcare group.
Mediclinic comprises 74 hospitals and 40 clinics. Mediclinic Southern Africa operates 49
hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than
8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics
in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6
hospitals and 34 clinics with more than 700 inpatient beds in the United Arab Emirates.
The platforms’ contributions to Group revenue for the financial year ended 31 March 2016
were 53.6% by Hirslanden, 30.8% by Mediclinic Southern Africa and 15.6% by Mediclinic
During February 2016, the combination of the Company (previously named Al Noor Hospitals
Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic
International Limited was completed. Mediclinic International Limited was a South African
based international private healthcare group founded in 1983 and listed on the JSE, the South
African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and
the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the
enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the
JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Brett Pollard/Ciara Martin
+44 (0)20 3727 1000
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 13/04/2017 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Email this JSE Sens Item to a Friend.